top of page

Outcomes by occurrence of immune-mediated adverse events with tremelimumab plus duralumab in the Phase 3 HIMALAYA study in unresctable hepatocellar carsinoma

Outcomes by occurrence of immune-mediated adverse events with tremelimumab plus duralumab in the Phase 3 HIMALAYA study in unresctable hepatocellar carsinoma.


天下仁心醫療集團

Humanity and Health Medical Group

​日 間 醫 療 中 心 牌 照 編 號 DP000128

©2025 天下仁心醫療集團 版權所有 Humanity and Health Medical Group Copyright

bottom of page